Dr. Markman on Precision Medicine in Ovarian Cancer
November 30th 2018Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the impact of precision medicine in ovarian cancer.
Dr. Salgia on FDA Approval of Lorlatinib in ALK+ NSCLC
November 3rd 2018Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.
City of Hope President Elected to Distinguished National Academy of Medicine
Michael A. Caligiuri, MD, president of City of Hope National Medical Center, and Deana and Steve Campbell Physician-in-Chief Distinguished Chair, has been elected to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.
Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC
February 19th 2018Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.
Dr. Raz on the Impact of the ALCHEMIST Trial on the Treatment of Patients With Lung Cancer
January 31st 2018Dan J. Raz, MD, MAS, co-director, Lung Cancer and Thoracic Oncology Program, assistant professor, Division of Thoracic Surgery, Department of Surgery, City of Hope, discusses the subsets of the ALCHEMIST trial.
Dr. Kim on the Safety of Immune Checkpoint Inhibition in Surgical Patients With Lung Cancer
January 31st 2018Jae Y. Kim, MD, chief, Division of Thoracic Surgery, Department of Surgery, assistant professor, Department of Surgery, City of Hope, discusses the use of immune checkpoint inhibitors in surgical patients with lung cancer.
Dr. Massarelli on First-Line ALK+ NSCLC Treatment
January 30th 2018Erminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).